Jasper Therapeutics appoints Herb Cross as CFO; Jeet Mahal continues as COO

Jasper Therapeutics, Inc.

Herb Cross, age 51, appointed CFO and Corporate Secretary effective Sept 22, 2023; prior CFO at Atreca.
Cross receives $460k base salary, 45% annual bonus target, $100k sign-on bonus.
Granted option to purchase 550,000 shares at $0.78/share; vests over 4 years (25% cliff at 1 yr, then monthly).
Jeet Mahal transitions from dual CFO/COO role to solely COO.
Option is an inducement grant under Nasdaq Listing Rule 5635(c)(4).

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Herb Cross

Chief Financial Officer and Corporate Secretary

JSPR · Jasper Therapeutics, Inc.

Effective: 2023-09-22
Filed: September 25, 2023, 7:59 PM ET

On September 21, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Herb Cross, age 51 , as its Chief Financial Officer and Corporate Secretary.

Role change

Jeet Mahal

Chief Operating Officer

JSPR · Jasper Therapeutics, Inc.

Effective: 2023-09-22
Successor: Herb Cross
Filed: September 25, 2023, 7:59 PM ET

the Board approved the transition of Jeet Mahal, the Company’s Chief Financial Officer and Chief Operating Officer, to serve solely as the Company’s Chief Operating Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Herb Cross was appointed as Chief Financial Officer and Corporate Secretary at Jasper Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer and Corporate Secretary

Exact text from the filing

On September 21, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Herb Cross, age 51 , as its Chief Financial Officer and Corporate Secretary.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeet Mahal changed role as Chief Operating Officer at Jasper Therapeutics, Inc..

Action: transitioned to solely COO
Role: Chief Operating Officer

Exact text from the filing

the Board approved the transition of Jeet Mahal, the Company’s Chief Financial Officer and Chief Operating Officer, to serve solely as the Company’s Chief Operating Officer.

View on SEC.gov

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-078927

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.